February 2026 Pipeline News Digest — Hot Tip Alerts

Our February pipeline news briefing is now available in the Athena BDA Insights Hub, covering the highest-priority Phase 3 results, recent approvals and acquisition activity shaping the pharma landscape.

Three standout updates this month:

Bepirovirsen — Hepatitis B — GSK

Strong Phase 3 results in Hepatitis B targeting a potential “functional cure”, with peak sales forecasts reaching around $2B. A functional cure would reset the treatment paradigm in a chronic, lifelong-therapy market, so expect commercial planning to move quickly.

Envudeucitinib — Psoriasis — Alumis

Positive Phase 3 data in psoriasis alongside accelerating commercial hiring puts this oral immunology asset firmly on launch watch. Hiring velocity is often the earliest reliable signal that a biotech is building out for launch.

Obefazimod — Ulcerative Colitis — Abivax

Momentum is building in ulcerative colitis following takeover speculation from Eli Lilly, with peak sales expectations of around $1.5B. If an acquisition lands, the commercial stakeholder map changes materially — worth tracking on both sides.

What else is in the full digest

The full February digest includes 11 priority brands with concise news catalyst summaries and direct source links.

Read the full briefing in our Athena BDA Insights Hub.